Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Sites are now starting to recruit patients. Please check back often to find an open site in your location.


Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis - IM014-029

Updated: 5 October, 2020   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 2


  • Gender(s)

  • 18-65

    Age Range

  • 65


  • Recruiting

Treatment Options

Study Arms
Experimental: pSS: branebrutinib
Drug: branebrutinib
Placebo Comparator: pSS: placebo
Drug: branebrutinib placebo
Experimental: RA: branebrutinib followed by abatacept
Drug: branebrutinib Drug: abatacept
Placebo Comparator: RA: placebo followed by abatacept
Drug: abatacept Drug: branebrutinib placebo
Experimental: SLE: branebrutinib
Drug: branebrutinib
Placebo Comparator: SLE: placebo
Drug: branebrutinib placebo

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: Sub-study for Systemic Lupus Erythematosus (SLE) - Active SLE as defined by the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) classification - Diagnosed with SLE more than 24 weeks before screening visit Sub-study for primary Sjögren's Syndrome (pSS) - Moderate to severe pSS, meeting ACR-EULAR classification criteria Sub-study for active Rheumatoid Arthritis (RA) - Moderate to severe adult-onset RA - ACR global functional status class I to III Women and men must agree to follow instructions for methods of contraception. Exclusion Criteria: Sub-study for Systemic Lupus Erythematosus - Certain other autoimmune diseases and overlap syndromes Sub-study for primary Sjögren's Syndrome - Certain other immune-mediated diseases, active fibromyalgia, or other medical conditions Sub-study for Rheumatoid Arthritis (RA) - Diagnosis with juvenile arthritis or idiopathic arthritis before age 16 For all sub-studies: - History of any significant drug allergy - Active infection, significant concurrent medical condition, or clinically significant abnormalities Other protocol defined inclusion/exclusion criteria could apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com